| Drug General Information |
| Drug ID |
D0FA6S
|
| Former ID |
DIB002760
|
| Drug Name |
Altiratinib
|
| Indication |
Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48]
|
Phase 1 |
[1]
|
|---|
| Company |
Deciphera pharmaceuticals
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Target and Pathway |
| Target(s) |
Vascular endothelial growth factor receptor 2 |
Target Info |
Antagonist |
[2]
|
|---|
| Angiopoietin 1 receptor |
Target Info |
Inhibitor |
[2]
|
| Hepatocyte growth factor receptor |
Target Info |
Inhibitor |
[2]
|
|
KEGG Pathway
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
Cytokine-cytokine receptor interaction
|
|
Endocytosis
|
|
PI3K-Akt signaling pathway
|
|
VEGF signaling pathway
|
|
Focal adhesion
|
|
Proteoglycans in cancerhsa04014:Ras signaling pathway
|
|
HIF-1 signaling pathway
|
|
Rheumatoid arthritishsa04014:Ras signaling pathway
|
|
Axon guidance
|
|
Adherens junction
|
|
Bacterial invasion of epithelial cells
|
|
Epithelial cell signaling in Helicobacter pylori infection
|
|
Malaria
|
|
Pathways in cancer
|
|
Transcriptional misregulation in cancer
|
|
Proteoglycans in cancer
|
|
MicroRNAs in cancer
|
|
Renal cell carcinoma
|
|
Melanoma
|
|
Central carbon metabolism in cancer
|
|
NetPath Pathway
|
IL2 Signaling PathwayNetPath_8:Wnt Signaling Pathway
|
|
PANTHER Pathway
|
Angiogenesis
|
|
VEGF signaling pathwayP00005:Angiogenesis
|
|
Pathway Interaction Database
|
HIF-2-alpha transcription factor network
|
|
Beta3 integrin cell surface interactions
|
|
Signaling events mediated by TCPTP
|
|
SHP2 signaling
|
|
S1P1 pathway
|
|
VEGF and VEGFR signaling network
|
|
Integrins in angiogenesis
|
|
Signaling events mediated by VEGFR1 and VEGFR2
|
|
Notch-mediated HES/HEY networkangiopoietinreceptor_pathway:Angiopoietin receptor Tie2-mediated signaling
|
|
SHP2 signalingmet_pathway:Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)
|
|
Arf6 signaling events
|
|
Posttranslational regulation of adherens junction stability and dissassembly
|
|
Direct p53 effectors
|
|
Syndecan-1-mediated signaling events
|
|
Stabilization and expansion of the E-cadherin adherens junction
|
|
a6b1 and a6b4 Integrin signaling
|
|
FGF signaling pathway
|
|
Regulation of retinoblastoma protein
|
|
Reactome
|
Neurophilin interactions with VEGF and VEGFR
|
|
VEGF binds to VEGFR leading to receptor dimerization
|
|
Integrin cell surface interactions
|
|
EPHA-mediated growth cone collapse
|
|
VEGFA-VEGFR2 Pathway
|
|
VEGFR2 mediated cell proliferationR-HSA-210993:Tie2 Signaling
|
|
RAF/MAP kinase cascadeR-HSA-416550:Sema4D mediated inhibition of cell attachment and migration
|
|
WikiPathways
|
Focal Adhesion
|
|
Nifedipine Activity
|
|
Cardiac Progenitor Differentiation
|
|
Signaling by VEGF
|
|
AngiogenesisWP363:Wnt Signaling Pathway Netpath
|
|
Cell surface interactions at the vascular wall
|
|
AngiogenesisWP366:TGF beta Signaling Pathway
|
|
Signaling of Hepatocyte Growth Factor Receptor
|
|
Extracellular vesicle-mediated signaling in recipient cells
|
|
Signaling Pathways in Glioblastoma
|
|
miR-targeted genes in squamous cell - TarBase
|
|
miR-targeted genes in muscle cell - TarBase
|
|
miR-targeted genes in lymphocytes - TarBase
|
|
miR-targeted genes in epithelium - TarBase
|
|
Semaphorin interactions
|
| References |
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800040094) |
|---|
| REF 2 | Clinical pipeline report, company report or official report of Deciphera Pharmaceuticals. |
|---|
